Using new technologies, researchers have developed a deeper understanding of how cells function, changing conceptions of disease.

A cellular computing error wreaks havoc on vision.

New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

A Novartis experimental drug in clinical trial aims to block liver cancer growth

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.

Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.